Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Smith Giri

Showing results (181-190 of 193) with videos related to

Pageof 20
Sort By:
The Oncologist|March 19, 2022
Use of Single-Item Self-Rated Health Measure to Identify Frailty and Geriatric Assessment-Identified Impairments Among Older Adults with CancerSmith Giri, Nabiel Mir, Mustafa Al-Obaidi, et al.
Journal of Geriatric Oncology|October 8, 2023
Implementation of the Web-Enabled Cancer & Aging Resilience Evaluation (WeCARE) in an outpatient oncology settingChristian Harmon, Mackenzie Fowler, Smith Giri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2021
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple MyelomaLuciano J Costa, Saurabh Chhabra, Eva Medvedova, et al.
Frontiers in Drug Safety and Regulation|September 22, 2025
Measurement error and bias in real-world oncology endpoints when constructing external control armsBenjamin Ackerman, Ryan W Gan, Craig S Meyer, et al.
American Journal of Hematology|June 22, 2022
Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapySusan Bal, Binod Dhakal, Rebecca W Silbermann, et al.
The Lancet. Haematology|September 30, 2023
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trialLuciano J Costa, Saurabh Chhabra, Eva Medvedova, et al.
American Journal of Epidemiology|February 6, 2026
Quantitative bias analyses to address measurement error in time-to-event endpointsBenjamin Ackerman, Ryan W Gan, Youyi Zhang, et al.
British Journal of Cancer|June 7, 2024
Anthropometric traits and risk of multiple myeloma: differences by race, sex and diagnostic clinical featuresKevin D Arnold, Krystle L Ong, Gayathri Ravi, et al.
Journal of Geriatric Oncology|September 17, 2024
Function, cognition, and quality of life among older adults with lung cancer who live alone: A prospective cohort studySurbhi Singhal, Louise C Walter, Alexander K Smith, et al.
The Oncologist|December 21, 2018
Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective AnalysisSteven M Bair, Lauren E Strelec, Tatyana A Feldman, et al.
Pageof 20

Showing results (181-190 of 193) with videos related to

Sort By:
Pageof 20
The Oncologist|March 19, 2022
Use of Single-Item Self-Rated Health Measure to Identify Frailty and Geriatric Assessment-Identified Impairments Among Older Adults with CancerSmith Giri, Nabiel Mir, Mustafa Al-Obaidi, et al.
Journal of Geriatric Oncology|October 8, 2023
Implementation of the Web-Enabled Cancer & Aging Resilience Evaluation (WeCARE) in an outpatient oncology settingChristian Harmon, Mackenzie Fowler, Smith Giri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2021
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple MyelomaLuciano J Costa, Saurabh Chhabra, Eva Medvedova, et al.
Frontiers in Drug Safety and Regulation|September 22, 2025
Measurement error and bias in real-world oncology endpoints when constructing external control armsBenjamin Ackerman, Ryan W Gan, Craig S Meyer, et al.
American Journal of Hematology|June 22, 2022
Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapySusan Bal, Binod Dhakal, Rebecca W Silbermann, et al.
The Lancet. Haematology|September 30, 2023
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trialLuciano J Costa, Saurabh Chhabra, Eva Medvedova, et al.
American Journal of Epidemiology|February 6, 2026
Quantitative bias analyses to address measurement error in time-to-event endpointsBenjamin Ackerman, Ryan W Gan, Youyi Zhang, et al.
British Journal of Cancer|June 7, 2024
Anthropometric traits and risk of multiple myeloma: differences by race, sex and diagnostic clinical featuresKevin D Arnold, Krystle L Ong, Gayathri Ravi, et al.
Journal of Geriatric Oncology|September 17, 2024
Function, cognition, and quality of life among older adults with lung cancer who live alone: A prospective cohort studySurbhi Singhal, Louise C Walter, Alexander K Smith, et al.
The Oncologist|December 21, 2018
Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective AnalysisSteven M Bair, Lauren E Strelec, Tatyana A Feldman, et al.
Pageof 20